Biochemical pharmacology ppt powerpoint presentation outline slide download

So basically your body has these enzymes that break down whatever meds you take. Most of the action happens in your liver with this cytochrome P450 family - they're like the main cleanup crew. But here's the thing: people's genetics make their enzymes work at totally different speeds. That's why your friend might need way less of something than you do. The enzymes directly control how long drugs stick around and how well they work. Oh, and certain foods or other drugs can speed up or slow down these enzymes, which honestly makes drug interactions super tricky to predict sometimes.

So receptor-ligand stuff pretty much controls how your drug's gonna work. Binding affinity tells you dosing - tighter binding means less drug needed. Selectivity's huge though, that's what separates hitting your target vs causing nasty side effects. Partial agonists are honestly way smarter than full ones because they plateau out. Like buprenorphine vs fentanyl - night and day difference for treating addiction. Oh, and residence time's sneaky important too. Some drugs stick around and keep working even when blood levels tank. When you're setting up studies, definitely check both potency and selectivity across receptor families. That'll give you a real sense of your therapeutic window.

Okay so competitive inhibitors literally compete with your drug for the same spot on the enzyme - like fighting over a parking space. If you pump up the drug dose, you can beat them out pretty easily. Non-competitive ones are way more annoying though. They bind somewhere totally different and mess up the whole enzyme shape, so it doesn't matter how much drug you give - it's still gonna be less effective. That's honestly the most frustrating part about non-competitive inhibition. You can't just throw more drug at the problem and call it a day. Always figure out which type you're dealing with before planning doses.

So basically, pharmacogenomics looks at your DNA to figure out how you'll process different meds. Like, your CYP450 enzymes can make you metabolize warfarin or antidepressants super fast or really slow. Pretty wild that we can use genetics as a cheat sheet for prescribing, right? No more guessing games with patients - you know exactly what'll work and what might cause problems. I'd start with CYP2D6 and CYP2C19 testing for psych meds. That's where you'll actually see results fast. Honestly beats the old trial-and-error nightmare most people go through.

Dude, bioavailability is huge for drug development. It shows what percentage of your dose actually gets into circulation and stays active. I've seen brilliant compounds tank because only like 5% survived first-pass metabolism - such a waste. This number literally dictates everything: your dosing, delivery route, whether it'll work at all. That's why IV doses are so different from oral ones for the same drug. Honestly, check those bioavailability numbers early or you'll end up with an amazing molecule that's completely useless in practice. Don't make that mistake.

So basically allosteric modulators don't compete for the main binding site like regular agonists and antagonists do. They hit a totally different spot on the receptor and just tweak how well it responds to its natural ligand. It's more like adjusting volume than hitting play/stop, if that makes sense. Way more subtle control. The cool thing is they're generally safer since they can only work when the body's natural stuff is already there. PAMs boost the signal, NAMs dial it down - honestly pretty elegant compared to just blocking everything. They're becoming huge in drug development for exactly this reason.

Dude, the targeted nanocarrier stuff is insane right now. Those lipid nanoparticles from the COVID vaccines? They're basically repurposing them for cancer drugs now. Smart polymers that actually respond to pH changes in sick tissue are huge too - way cooler than it sounds. CRISPR delivery keeps getting better, though honestly the whole field moves so fast I can barely keep track. Oh, and antibody-guided delivery systems for hitting specific organs. That's pretty wild. If you're doing any drug dev work, definitely check out stimuli-responsive carriers. Clinical results have been solid lately. Actually might be the most promising direction right now.

So basically, fat-loving drugs go everywhere - they slip right through cell walls and into your brain, plus they love hanging out in fatty tissue. Water-loving ones? They're pretty much stuck in your blood and can't get into cells as easily. Here's the weird part though - when it comes to getting rid of them, it flips. Your liver has to break down the fatty drugs first before your kidneys can dump them, but water-soluble ones just get filtered out super fast. Bottom line: fat-soluble drugs stick around way longer and spread everywhere.

Honestly, target specificity is the worst part - your drug hits the wrong stuff and causes nasty side effects. Bioavailability sucks too because compounds either break down too fast or never reach where they need to go. Cancer drugs especially get screwed by resistance since cells just evolve around whatever you throw at them. The regulatory maze costs a fortune and takes forever. Computational modeling helps a ton if you do it early, plus good biomarkers so you're not shooting blind about who'll actually benefit. Still feels like gambling half the time though.

Oh man, drug interactions are such a pain to deal with but super important. Basically what happens is two drugs fight over the same pathway in your body - one builds up dangerously while the other stops working properly. Elderly patients get hit the worst since they're juggling like 10 different meds. Classic example? Warfarin plus antibiotics equals your patient bleeding everywhere. I learned that one the hard way during rotations! Always double-check interactions before prescribing, especially with those finicky drugs that have narrow safety margins.

Think of the blood-brain barrier as this super strict bouncer that decides what gets into your brain. It's honestly the most annoying part of developing neurological drugs. Those tight junctions between cells block most compounds from crossing over. You'll want to focus on molecular size and how fat-soluble your drug is - that stuff matters way more than people realize. Transport mechanisms are key too. I've seen so many promising compounds work perfectly in the lab but completely flop in actual patients because nobody checked if they could even reach brain tissue. Always test BBB penetration early or you're just wasting time.

So basically, you can predict how patients will respond to drugs by checking their genetic variants, protein levels, or metabolic markers beforehand. Pharmacogenomic testing shows if someone's a fast or slow metabolizer. Tumor biomarkers tell you if targeted therapy will actually work - like checking HER2 status before using trastuzumab. Honestly, it's pretty amazing for personalized medicine, though the testing can get expensive. The trick is matching biomarkers to how the drug actually works. I'd start by finding which biomarkers are already clinically validated in your area, then build your testing around those.

Okay so the big ones are informed consent and patient safety - basically making sure people actually get what they're signing up for, especially vulnerable groups. Animal testing is brutal honestly, probably the hardest part ethically. Then you've got the whole pricing nightmare where life-saving meds cost a fortune. Data privacy matters too, plus avoiding conflicts of interest when money's involved. Oh and equitable access - can't just help rich patients, you know? My take? If you wouldn't want to explain your choice to someone's mom, don't do it.

Look, chronic diseases mess with everything when it comes to prescribing. Kidney or liver problems? Standard doses might be way too much or do absolutely nothing. Diabetic patients have crappy circulation and heal poorly, so you'll need different antibiotics or change when you give them. Heart failure means avoiding anything that makes the heart work harder - which is honestly a lot of drugs. The real headache though is all the meds they're already taking. Drug interactions become this massive puzzle. I always pull their recent labs first to see how their organs are doing, then go through their entire med list. Saves you from some nasty surprises later.

So basically cancer cells are sneaky little bastards that fight back in multiple ways. They'll pump drugs out using these transporter proteins like P-glycoprotein. Or they mutate the targets so your drugs can't even bind properly anymore. Some activate totally different survival pathways to work around whatever you're blocking. Plus they ramp up DNA repair and mess with drug metabolism. It's honestly pretty fascinating how adaptable they are. That's why combo therapies work better - hitting multiple pathways makes it way harder for them to develop resistance.